Somewhat unusually, it said it would also like to see "more information from the company about the comparison between pembrolizumab plus chemotherapy with atezolizumab plus chemotherapy." ...

For those receiving pembrolizumab, the therapy was initiated at 2-6 weeks ... with all also receiving the immune checkpoint ...

Combining the checkpoint inhibitor atezolizumab with targeted therapy led to improvements in overall survival in patients ...

Roche claimed FDA approval for Tecentriq (atezolizumab) in the US last year ... While Merck's Keytruda (pembrolizumab) dominates first-line treatment of more advanced NSCLC, it has been behind ...

In the adjuvant space, Leal highlighted IMpower010 (NCT02486718; atezolizumab) and KEYNOTE-091 (NCT02504372; pembrolizumab). Collectively, these therapies have substantially expanded the treatment ...

Medscape Medical News, September 17, 2024 ESMO 2024 Pembrolizumab Plus CCRT Improves ... 2024 Alert FDA OKs Subcutaneous Atezolizumab for Multiple Cancers Subcutaneous injections save time ...

Exelixis, Inc. EXEL reported better-than-expected third-quarter results. Its shares have risen following the announcement.

Exelixis’s Cabometyx continues to drive revenue growth, prompting a raised 2024 forecast to $2.15–$2.2 billion. Read my EXEL ...

Read more about A trial of chemoradiotherapy, pembrolizumab, and olaparib for small cell lung ... A trial of lurbinectedin and atezolizumab to improve treatment for small cell lung cancer (IMforte) ...

Current therapeutic options for SCLC include Merck & Co’s Keytruda (pembrolizumab), Bristol ... Imfinzi (durvalumab), and ...

Clinical research conducted with participation from Florida Cancer Specialists & Research Institute, LLC (FCS) continues to ...